Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
CNY 21.0
(0.92%)
CNY 21.0
(0.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.88 Billion CNY | 69.71% |
| 2022 | 1.1 Billion CNY | 89.02% |
| 2021 | 586.65 Million CNY | 248.27% |
| 2020 | 168.44 Million CNY | -46.5% |
| 2019 | 314.87 Million CNY | -69.24% |
| 2018 | 1.02 Billion CNY | 85.12% |
| 2017 | 552.93 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.39 Billion CNY | 6.46% |
| 2024 Q1 | 2.24 Billion CNY | 19.36% |
| 2024 Q3 | 2.59 Billion CNY | 8.42% |
| 2023 Q4 | 1.88 Billion CNY | 22.48% |
| 2023 Q3 | 1.53 Billion CNY | 2.64% |
| 2023 FY | 1.88 Billion CNY | 69.71% |
| 2023 Q2 | 1.49 Billion CNY | 10.6% |
| 2023 Q1 | 1.35 Billion CNY | 22.05% |
| 2022 Q3 | 926.5 Million CNY | 20.27% |
| 2022 Q4 | 1.1 Billion CNY | 19.68% |
| 2022 FY | 1.1 Billion CNY | 89.02% |
| 2022 Q2 | 770.33 Million CNY | 15.91% |
| 2022 Q1 | 664.57 Million CNY | 13.28% |
| 2021 Q4 | 586.65 Million CNY | 42.86% |
| 2021 Q2 | 379.43 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 FY | 586.65 Million CNY | 248.27% |
| 2021 Q3 | 410.64 Million CNY | 8.23% |
| 2020 Q4 | 168.44 Million CNY | 0.0% |
| 2020 FY | 168.44 Million CNY | -46.5% |
| 2020 Q2 | 152.7 Million CNY | 0.0% |
| 2019 FY | 314.87 Million CNY | -69.24% |
| 2018 FY | 1.02 Billion CNY | 85.12% |
| 2017 FY | 552.93 Million CNY | 0.0% |